Loading...
Market
Will a Phase II clinical trial for MED6-189 be published by September 30, 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
ClinicalTrials.gov and scientific journals
Story
Kalihinol Analog MED6-189 Shows Promise Against Drug-Resistant Malaria Parasite
Sep 27, 2024, 07:28 AM
A synthetic compound, MED6-189, a kalihinol analog, has shown promise against both drug-sensitive and drug-resistant strains of the malaria parasite Plasmodium falciparum. The compound disrupts apicoplast function and vesicular trafficking in the parasite, effectively killing it. This discovery, highlighted in a study published in Science, demonstrated efficacy in a humanized mouse model of malaria. Research by @UCRiverside and @ScienceMagazine indicates that MED6-189 could be a significant advancement in the fight against malaria.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Positive results for B-cell malignancies • 25%
Positive results for autoimmune diseases • 25%
Negative results for both • 25%
Mixed results • 25%